抗心肌抗体(AHA)是机体产生针对自身心肌蛋白分子的抗体总称,介导心肌免疫损伤,促使病毒性心肌炎(VMC)和扩张型心肌病(DCM)的发生发展。近年来越来越多的临床证据显示,AHA在VMC和DCM患者体内表达具有高度敏感性和特异性。AHA的检测对VMC和DCM早期诊断、疾病风险评估和预后判断具有重要价值;而早期针对AHA选择临床用药,能有效防治疾病、改善患者预后。 Anti-myocardial antibodies (AHA) is the general body of antibodies against their own myocardial protein molecules, mediated myocardial damage, promote the development of viral myocarditis (VMC) and dilated cardiomyopathy (DCM). In recent years, more and more clinical evidence shows that AHA expression in VMC and DCM patients with high sensitivity and specificity. AHA detection of VMC and DCM early diagnosis, disease risk assessment and prognosis of great value; and early selection of clinical medication for AHA, can effectively prevent and cure diseases, improve patient prognosis.